Hypothesis

A coordinated decline across the hallmarks of aging is driven by loss of colonic butyrate‑producing bacteria, which removes a key microbial metabolite that simultaneously regulates epigenetic, metabolic, and immune pathways in the host.

Mechanistic rationale

Butyrate functions as a histone deacetylase inhibitor (HDACi) and a ligand for GPR109A on colonocytes and immune cells. Through HDAC inhibition, butyrate increases acetylation of FOXO3 and PGC‑1α promoters, enhancing stress‑resistance transcription and mitochondrial biogenesis. Simultaneously, GPR109A activation triggers β‑arrestin–biased signaling that suppresses NF‑κB–mediated inflammaging and promotes autophagy via AMPK activation. When butyrate‑producing taxa such as Faecalibacterium prausnitzii and Eubacterium rectale decline with age, these protective signals wane, leading to:

• Epigenetic drift – reduced histone acetylation at longevity loci
• Mitochondrial dysfunction – lowered PGC‑1α activity and oxidative phosphorylation
• Cellular senescence – increased p16^INK4a^ due to loss of FOXO3‑mediated cell‑cycle control
• Stem cell exhaustion – impaired colonocyte renewal from diminished HDACi‑dependent Wnt modulation
• Inflammaging – unchecked NF‑κB activity and cytokine production Thus, the microbiota‑butyrate axis acts as an upstream controller whose loss produces the correlated suite of aging phenotypes.

Testable predictions

1. Cross‑sectional correlation – Older adults with higher fecal butyrate concentrations will show younger epigenetic clocks (e.g., lower GrimAge), better mitochondrial respiration in peripheral blood mononuclear cells, lower serum IL‑6/TNF‑α, and higher colonic crypt proliferation markers.
2. Longitudinal intervention – A 12‑week, double‑blind, placebo‑controlled trial administering a defined consortium of butyrate‑producers plus a fermentable fiber (e.g., inulin) to participants aged 65‑80 will increase fecal butyrate by ≥30 % compared with placebo.
   • Primary outcomes: change in epigenetic age acceleration, mitochondrial oxidative capacity (Seahorse assay), and senescence-associated secretory phenotype (SASP) plasma factors.
   • Secondary outcomes: gut barrier integrity (serum zonaryl), frailty index, and cognitive composite score.
3. Mechanistic validation – In a subset undergoing sigmoidoscopy, colonic biopsies will reveal increased histone H3K27ac at FOXO3/PGC‑1α loci, decreased p16^INK4a^ staining, and higher LC3‑II/LC3‑I ratios indicative of autophagy.

Falsifiability

If the intervention fails to raise fecal butyrate to target levels, or if butyrate restoration does not produce concurrent improvements across at least three of the five hallmark domains (epigenetic, mitochondrial, senescence, stem cell, inflammation), the hypothesis that a single microbial‑metabolite axis orchestrates multi‑system aging is refuted. Conversely, concordant improvements would support the idea that targeting this upstream controller can mitigate aging as a coordinated program.

Novel insight beyond correlation

While prior work links dysbiosis to individual hallmarks, this hypothesis specifies how a single metabolite integrates epigenetic regulation, metabolic reprogramming, and immune tolerance through dual HDACi/GPCR signaling. It shifts focus from restoring generic diversity to reinstating a defined functional output—butyrate flux—as a leverage point for systemic rejuvenation.